| Naslov: | Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : final analysis of the GioTag study |
|---|
| Avtorji: | ID Hochmair, Maximilian J (Avtor)
ID Morabito, Alessandro (Avtor)
ID Hao, Desiree (Avtor)
ID Yang, Cheng-Ta (Avtor)
ID Soo, Ross A (Avtor)
ID Yang, James C-H (Avtor)
ID Gucalp, Rasim (Avtor)
ID Halmos, Balazs (Avtor)
ID Märten, Angela (Avtor)
ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (1,58 MB)
MD5: E5B817D1334C093553F6EC429C0A7178
PDF - Priloga, prenos (1,10 MB)
MD5: C384BC86E3FD51111A4BAD50BC370759
 URL - Izvorni URL, za dostop obiščite https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0740
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
|---|
| Povzetek: | Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment >/=10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. |
|---|
| Ključne besede: | non-small cell lung carcinoma -- therapy, drug therapy, afatinib, osimertinib, GioTag study |
|---|
| Status objave pri reviji: | V tisku |
|---|
| Verzija članka: | Založnikova različica članka |
|---|
| Kraj izida: | Velika Britanija |
|---|
| Založnik: | Future Medicine Ltd |
|---|
| Leto izida: | 2020 |
|---|
| Št. strani: | str. [1-10] |
|---|
| Številčenje: | Vol. 16, no. |
|---|
| PID: | 20.500.12556/DiRROS-12685  |
|---|
| UDK: | 616-006 |
|---|
| ISSN pri članku: | 1744-8301 |
|---|
| DOI: | 10.2217/fon-2020-0740 |
|---|
| COBISS.SI-ID: | 37424899 |
|---|
| Avtorske pravice: | © 2020 Maximilian J. Hochmair and other authors |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 14. 11. 2020;
Soavtorica iz Slovenije: Tanja Cufer;
|
|---|
| Datum objave v DiRROS: | 18.11.2020 |
|---|
| Število ogledov: | 1132 |
|---|
| Število prenosov: | 1005 |
|---|
| Metapodatki: |     |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
|
|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
